Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.008
  • Today's Change-0.001 / -11.11%
  • Shares traded12.98m
  • 1 Year change-27.27%
  • Beta1.3828
Data delayed at least 20 minutes, as of Feb 10 2026 05:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

  • Revenue in AUD (TTM)446.29k
  • Net income in AUD-12.15m
  • Incorporated1997
  • Employees9.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Syntara Ltd7.48m-12.26m57.16m107.00--3.55--7.64-0.0084-0.00540.00510.00990.4701--2.53---77.03-36.39-116.54-50.26-----163.86-78.37---953.380.0052--37.80-9.8310.31------
Amplia Therapeutics Ltd5.01m-7.93m59.00m1.00--1.37--11.78-0.0204-0.02040.01280.08370.1705--1.28---27.01-27.37-28.31-30.38-----158.46-180.53----0.0088---15.01156.11-45.93------
Clever Culture Systems Ltd6.52m1.68m60.84m17.0035.908.7631.879.330.00080.00080.00310.00320.69750.98296.37--18.01-36.7322.73-42.0077.05--25.82-281.211.63--0.2653--397.8630.08145.03--24.71--
Proteomics International LaboratoriesLtd3.31m-8.11m76.81m----5.77--23.19-0.0605-0.06050.02470.08050.2582--12.02---63.57-63.62-68.88-71.91-----246.18-222.10----0.021--1.3415.81-27.27---54.88--
Prescient Therapeutics Ltd225.61k-7.32m78.86m3.00--5.30--349.56-0.0091-0.00910.00030.01410.0129--0.9582---41.90-31.70-49.69-34.33-----3,245.66-2,146.75---590.480.00---67.1926.2411.11------
Imugene Ltd0.00-69.02m80.38m0.00--1.22-----0.3161-0.31610.000.2050.00-------58.75-48.72-75.21-53.73------------0.1913------53.89--38.40--
Rhythm Biosciences Ltd3.33m-3.83m83.40m----112.19--25.08-0.0134-0.01340.01240.00231.5398.7967.11---176.04-146.24-469.96-197.40-10.4422.48-115.14-287.420.8046-53.890.6266--90.87135.1444.15---12.61--
LTR Pharma Ltd2.10m-5.59m89.05m----2.81--42.33-0.0333-0.03330.01260.17410.1183--8.22---31.44---32.47-------265.90--45.76-62.540.00--4,164.38--19.57------
Cynata Therapeutics Ltd227.70k-9.39m90.23m0.00--14.35--396.28-0.0453-0.04530.00110.02650.0292--2.16---120.50-48.36-142.29-53.09-----4,124.10-576.20---1,268.000.00---45.4928.123.63------
Bioxyne Ltd28.43m4.90m94.08m16.0018.107.3316.543.310.00230.00230.01320.00572.166.3017.06--37.31-28.1755.76-38.1636.3235.9717.24-24.141.90--0.1125--204.8765.94138.29--127.89--
Alterity Therapeutics Ltd446.29k-12.15m97.88m9.00--1.94--219.32-0.002-0.0020.000070.00470.0137--5,578.6349,587.78-37.23-49.00-43.12-57.35-----2,721.96-9,708.51---211.820.0037--66.2791.9736.48------
Tetratherix Ltd1.14m-9.43m103.00m----7.00--90.14-0.1873-0.18730.02270.54140.0688--2.22---56.71---76.72---172.06---824.89-----98.750.0697--32.30---269.05------
Island Pharmaceuticals Ltd58.80k-3.92m113.00m----13.86--1,921.80-0.0224-0.02240.00030.03030.0117--0.1099---77.95-72.12-90.37-81.53-----6,666.91-19,239.15---162.890.00--1,148.41---36.86------
Arovella Therapeutics Ltd525.53k-7.51m118.92m14.00--5.86--226.28-0.0067-0.00670.00050.01690.0301-------43.05-75.94-47.90-90.89-----1,428.87-2,386.13----0.00--237.44-1.8214.14--1.23--
Paradigm Biopharmaceuticals Ltd7.11m-18.77m136.61m----5.79--19.23-0.047-0.0470.01830.05440.2684--1.14---70.91-67.55-80.99-75.9899.7199.24-264.18-527.01---9,722.290.0003--10.298.8768.04------
Actinogen Medical Ltd685.26k-14.73m140.45m----7.62--204.95-0.005-0.0050.00020.00580.0299--0.0907---64.34-53.87-76.58-59.25-----2,149.88-3,680.96---231.810.1511--135.4648.76-12.94--10.81--
Data as of Feb 10 2026. Currency figures normalised to Alterity Therapeutics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

4.88%Per cent of shares held by top holders
HolderShares% Held
Pengana Capital Ltd.as of 31 Oct 2025355.42m3.27%
Pictet Asset Management SAas of 30 Jun 202579.28m0.73%
Norges Bank Investment Managementas of 30 Jun 202561.67m0.57%
Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 202534.10m0.31%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.